Skip to content
CancerIndex

Publication

Real-world outcomes after Mirvetuximab Soravtansine treatment for recurrent ovarian Cancer: Results from a university setting.

Anna V Jones, Rachel L Furuya, L Stewart Massad, Dong Wang, Mary M Mullen, Brooke E Sanders

Gynecologic oncology reportsOct 1, 2026PMID 42733650doi:10.1016/j.gore.2026.102197 PMC13571410Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 29, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260929-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

BACKGROUND: Mirvetuximab Soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor alpha (FRα), expressed in most ovarian cancers. Pivotal trials reported favorable outcomes but used stringent eligibility criteria, and real-world effectiveness and toxicity remain incompletely…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.